Aspen Pharmacare and Adcock Ingram, two JSE-listed pharmaceutical manufacturers, are looking to diversify their businesses after the decline in COVID-19 vaccine sales. They are both confident that they can weather the storm and continue to grow their businesses. They have a strong track record of innovation and are well-positioned to take advantage of new opportunities.
Read the full article on the Daily Maverick.